Search results for "Epidermoid Carcinoma"

showing 10 items of 64 documents

bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus

1996

The bcl-2 proto-oncogene is a known inhibitor of apoptosis and may be an important regulator of tumor growth. In the present study, bcl-2-protein expression was investigated by immunohistochemistry and correlated with prognosis in a series of 150 potentially curatively resected squamous-cell carcinomas of the esophagus. For comparison, bcl-2-protein expression was analyzed in normal esophageal mucosa, severe squamous dysplasias and carcinomas in situ. bcl-2 immunoreactivity was found in 40 out of 150 invasive squamous-cell carcinomas; the remaining carcinomas were completely negative. bcl-2-protein expression was found more frequently among poorly differentiated than among well-differentiat…

AdultCancer ResearchPathologymedicine.medical_specialtyEsophageal NeoplasmsCellGene ExpressionBiologyInhibitor of apoptosisProto-Oncogene MasProto-Oncogene ProteinsGene expressionmedicineHumansEsophagusAgedAged 80 and overMucous MembraneEsophageal diseaseMiddle AgedEsophageal cancerPrognosismedicine.diseaseSurvival Ratemedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2OncologyEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryCarcinoma in SituInternational Journal of Cancer
researchProduct

Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uter…

2004

Abstract Hypoxia inducible factor-1α (HIF-1α) has been proposed as a candidate endogenous marker of tumor hypoxia and as a molecular mediator of hypoxia-driven malignant progression and acquired treatment resistance. In this study, HIF-1α expression in 68 biopsies of oxygenation measurement tracks from squamous cell carcinomas of the uterine cervix of 38 patients was assessed. Expression of HIF-1α was commonly found to increase as a function of distance from microvessels, at the center of tumor cell aggregations, and in the vicinity of necrotic areas. However, there was no correlation of HIF-1α expression with median oxygen tension (oxygen partial pressure; pO2) and hypoxic fractions (hypox…

AdultCancer ResearchPathologymedicine.medical_specialtyPartial PressureCellUterine Cervical NeoplasmsEndogenyBiologyGene expressionmedicineHumansAgedNeoplasm StagingCell NucleusTumor hypoxiaOxygenationHypoxia (medical)Middle AgedHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaOxygen tensionOxygenmedicine.anatomical_structureOncologyEpidermoid carcinomaCarcinoma Squamous CellFemalemedicine.symptomTranscription FactorsCancer research
researchProduct

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…

2009

Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…

AdultDiarrheaMalemedicine.medical_specialtyNeutropeniaTime FactorsEsophageal NeoplasmsCetuximabPhases of clinical researchKaplan-Meier EstimateAntibodies Monoclonal Humanizedmedicine.disease_causeGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalAgedCross-Over StudiesDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalNauseaHematologyMiddle AgedCombined Modality TherapySurvival AnalysisChemotherapy regimenSurgeryTreatment OutcomeOncologyEpidermoid carcinomaFluorouracilResponse Evaluation Criteria in Solid TumorsCarcinoma Squamous CellFemaleFluorouracilKRASCisplatinbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Evolution of oral neoplasm in an andalusian population (Spain)

2018

Background Head and neck cancer are one of the most common neoplasm pathologies in humans. The aim of this study was to analyze the type, characteristics, treatment and evolution of oral neoplasm or precancerous lesion in a sample of Andalusian population (Spain) derived from the Oncology Rehabilitation Hospital Unit during a period of 20 years. Material and Methods A retrospective descriptive study was carried out during the years 1991 and 2011 analyzing the type, characteristics, treatment and follow-up of oral neoplasm in the Oral and Maxillofacial Surgery Unit of the Universitary Hospital “Virgen del Rocío”. The inclusion criteria were patients whose underlying pathology was any type of…

AdultMale0301 basic medicineRehabilitation hospitalmedicine.medical_specialtyTime FactorsPopulationYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansYoung adulteducationGeneral DentistryRetrospective Studieseducation.field_of_studybusiness.industryResearchHead and neck cancerRetrospective cohort studyOral NeoplasmMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.disease030104 developmental biologyOtorhinolaryngologyEpidermoid carcinomaSpain030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOral and maxillofacial surgeryFemaleMouth NeoplasmsSurgeryOral Surgerybusiness
researchProduct

Oral cancer: A multicenter study

2017

Background To determine the prevalence and clinicopathologic features of the oral cancer patients. Material and Methods Biopsy records of the participating institutions were reviewed for oral cancer cases diagnosed from 2005 to 2014. Demographic data and site of the lesions were collected. Sites of the lesion were subdivided into lip, tongue, floor of the mouth, gingiva, alveolar mucosa, palate, buccal/labial mucosa, maxilla and mandible. Oral cancer was subdivided into 7 categories: epithelial tumors, salivary gland tumors, hematologic tumors, bone tumors, mesenchymal tumors, odontogenic tumors, and others. Data were analyzed by descriptive statistics using SPSS software version 17.0. Resu…

AdultMaleCanadamedicine.medical_specialtyAsiaAdolescentYoung Adult03 medical and health sciences0302 clinical medicinestomatognathic systemTongueMucoepidermoid carcinomaPrevalencemedicineHumansOral mucosaYoung adultLabial MucosaChildGeneral DentistryAlveolar mucosaAgedAged 80 and overMouth neoplasmOral Medicine and Pathologybusiness.industryResearchCancer030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologystomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASFemaleMouth NeoplasmsSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma.

2010

Promoter hypermethylation of tumor suppressor genes is a common feature of primary cancer cells. However, at date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis are not yet been well defined. In the present study we analysed the methylation status of the gene hypermethylated in cancer-1 (hic1), a gene located on chromosome 17p13.3, a region frequently lost in HNSCC. We analysed 22 HNSCC samples and three cell lines using methylation specific PCR (MSP). We found hic1 methylated in 21 out of 22 samples and in all three cell lines. Treatment of the cell lines with the demethylating agent 5-Azacytidin (5-Aza) resulted in the demethylation…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingKruppel-Like Transcription FactorsBiologymedicine.disease_causechemistry.chemical_compoundCell Line TumormedicineHumansGenes Tumor SuppressorNeoplasm InvasivenessPromoter Regions GeneticneoplasmsAgedMethylationDNA MethylationMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaDemethylating agentGene Expression Regulation Neoplasticstomatognathic diseasesOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsCancer cellCancer researchAzacitidineCarcinoma Squamous CellFemaleOral SurgeryCarcinogenesisOral oncology
researchProduct

Expression of Bax, a pro-apoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma

1997

Samples of normal esophageal squamous epithelium (n = 10), severe squamous cell dyplasia (n = 22), carcinoma in situ (n = 15), invasive squamous cell carcinoma (n = 172), lymph-node metastasis (n = 21) and 2 permanent esophageal squamous cell carcinoma cell lines were analyzed immunohistochemically for Bax expression using a polyclonal anti-Bax antibody. Immunostaining was evaluated according to a score system (0–8 points) based on the percentage of positive tumor cells and the relative immunostaining intensity. Cytoplasmatic staining for Bax protein was found uniformly in all cell layers of the normal esophageal squamous epithelium. In contrast, a gradual loss of immunoreactivity for Bax w…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyEsophageal NeoplasmsCellBiologyMetastasisEsophagusProto-Oncogene ProteinsTumor Cells CulturedmedicineHumansEsophagusAgedbcl-2-Associated X ProteinAged 80 and overCarcinoma in situCancerMiddle AgedEsophageal cancermedicine.diseaseSurvival AnalysisNeoplasm Proteinsmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2OncologyEpidermoid carcinomaCarcinoma Squamous CellRegression AnalysisFemaleCarcinoma in SituImmunostainingInternational Journal of Cancer
researchProduct

Lymph node metastasis in lower lip squamous cell carcinoma in relation to tumour size, histologic variables and p27Kip1 protein expression.

2003

We studied a consecutive series of 95 patients undergoing radical surgical resection of lower lip squamous cell carcinoma (LLSCC) to assess the correlation between lymph node status and several prognostic variables, such as sex and age, tumour size, histologic grading, maximal microscopic tumour thickness, perineural infiltration and p27Kip1 protein status, to see which of these might be predictive of the development of lymph node metastases. Statistical analysis demonstrated a significant association between node status and tumour size, histological grading, maximal thickness, perineural invasion and p27Kip1 protein expression; additionally to node metastasis, low p27Kip1 protein expressio…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPrognostic variablePerineural invasionCell Cycle ProteinsMetastasisCarcinomamedicineHumansNeoplasm InvasivenessLymph nodeGrading (tumors)Agedbusiness.industryTumor Suppressor ProteinsHistologyMiddle AgedLymph node metastasis Sqamous cell Carcinoma Lower lip p27 tumour thcikness.medicine.diseasePrognosisImmunohistochemistrymedicine.anatomical_structureOncologyEpidermoid carcinomaLymphatic MetastasisLip NeoplasmsCarcinoma Squamous CellFemaleOral SurgerybusinessCyclin-Dependent Kinase Inhibitor p27Oral oncology
researchProduct

Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.

1997

BACKGROUND. Basaloid squamous cell carcinoma (BSCC) is a recently recognized, poorly differentiated variant of squamous cell carcinoma (SCC), which is located predominantly in the upper aerodigestive tract. METHODS. In this study, clinical and pathologic parameters of 17 BSCCs and 133 typical SCCs of the esophagus that underwent potentially curative resection (no distant metastases, no residual tumor) were compared. In addition, light microscopic, electron microscopic, and immunohistochemical features of BSCC were investigated, to determine whether this type of carcinoma could be differentiated from other poorly differentiated carcinomas of the esophagus. RESULTS. Light microscopic study sh…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyEsophageal NeoplasmsApoptosisEpitheliumDiagnosis DifferentialCytokeratinNecrosisSex FactorsCarcinoma BasosquamousmedicineCarcinomaHumansNeoplasm InvasivenessEsophagusBasaloid Squamous Cell CarcinomaAgedNeoplasm StagingAged 80 and overMucous Membranebusiness.industryCarcinoma in situS100 ProteinsAge FactorsCell DifferentiationMiddle Agedmedicine.diseasePrognosisAntigens DifferentiationImmunohistochemistryActinsSurvival Ratestomatognathic diseasesMicroscopy Electronmedicine.anatomical_structureOncologyEpidermoid carcinomaDysplasiaCarcinoma Squamous CellKeratinsHistopathologyFemalebusinessCarcinoma in SituCell DivisionCancer
researchProduct

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin…

1998

We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m(-2) day(-1) 5-FU on days 1-5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8-12 and 15-19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study;…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyAntineoplastic AgentsGastroenterologyGroup Blaw.inventionRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedChemotherapybusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryRegimenOncologyEpidermoid carcinomaHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellInterleukin-2Drug Therapy CombinationFemaleFluorouracilCisplatinbusinessProgressive diseasemedicine.drugCancer Immunology, Immunotherapy
researchProduct